As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales of the Spikevax® and Comirnaty® COVID-19 vaccines. Key suits were filed by third party mRNA and lipid pioneers that, while not having any mRNA-based products on the market themselves, leveraged their patent portfolios claiming a share of the billions of dollars in sales the vaccines have generated. Direct competitors Moderna and Pfizer+BioNTech also clashed in patent litigation beginning in 2022, with cases initiated in the United States and later expanding abroad.
Recent Posts
- Federal Circuit Finds No Due Process Violation Stems from Inconsistent Positions on Patent Ownership at PTAB, ITC
- UPC Issues First Permanent SEP Injunction: The Ramifications of Philips v. Belkin | IPWatchdog Unleashed
- Thaler Tells SCOTUS Refusing Copyright to AI-Generated Works Endangers Photo Copyrights, Too
- Amici Urge SCOTUS to Address Uncertainty Around ‘After-Arising Technology’ Question
- Other Barks and Bites for Friday, October 10: SCOTUS Invites SG’s Views on RiseandShine’s Trademark Issues; MPA Urges OpenAI to Address Sora 2 Infringement; and UPC to Add Third Panel to Court of Appeal